Medical News

RSS

Metropolitan Health Networks reports 2.9% increase in revenue for first-quarter 2010

Metropolitan Health Networks, Inc., a leading provider of healthcare services in Florida, today announced the financial results for their first quarter ended March 31, 2010.

4 May 2010

Reprints Desk launches ePrints NRx scientific article collection service

Derycz Scientific, Inc., the content repurposing company, today announced that its subsidiary Reprints Desk, an award-winning provider of information services and content workflow solutions, has launched ePrints NRx, a new scientific article collection service that simplifies the re-use of PDFs by medical marketers, brand managers and sales professionals.

4 May 2010

MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2010.

4 May 2010

Techne Corporation's consolidated net earnings up 17.2% for quarter ended March 31, 2010

Techne Corporation's consolidated net earnings for the quarter ended March 31, 2010 increased 17.2% to $32.4 million or $.87 per diluted share compared with $27.6 million or $.74 per diluted share for the quarter ended March 31, 2009. The increase in net earnings for the quarter was primarily due to a $4.7 million tax benefit, equating to $.12 per share, resulting from a foreign exchange tax loss on Techne's repatriation of 50 million pound sterling from R&D Systems Europe to its U.S. based parent.

From BiosPacific, Inc. 4 May 2010

Micronics receives FDA marketing clearance for ABORhCard

Micronics, Inc., a medical device development company, today announced that the U.S. Food and Drug Administration has granted the company 510(k) clearance to market its ABORhCard, a qualitative in vitro test that provides a simultaneous determination of an individual's ABO blood group and Rh factor status. It is not for use for blood bank processing of blood products, for determining RHD status for the purpose of administration of Rh immunoglobulin, or for screening purposes prior to transfusion.

4 May 2010

Glycos Biotechnologies announces international expansion into Malaysia

Glycos Biotechnologies, Inc., an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today announced the company's international expansion into Malaysia.

4 May 2010

Fresenius Medical Care's first-quarter net revenue up 13% to $2,882 million

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced its results for the first quarter of 2010.

4 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

Cerner, Fort HealthCare collaborate to create connected health community

Cerner Corporation announced a strategic partnership with Fort HealthCare, an integrated hospital and health system in Fort Atkinson, Wis., to create a connected health community. Fort HealthCare will work with Cerner to improve the quality of care and make care processes more efficient for more than 120,000 residents in the organization's service area through the use of Cerner Millennium® solutions.

4 May 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

4 May 2010

Australia to introduce plain cigarette packaging

Cigarettes in Australia will soon have to be sold in plain packaging to prevent consumers - and particularly children - from being influenced by tobacco advertising.

4 May 2010

Response Biomedical first-quarter total revenue down 43%

Response Biomedical Corporation today announced financial results for the first quarter ended March 31, 2010.

4 May 2010

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Impax Laboratories, Inc. today reported significant growth in the first quarter of 2010 due to an increase in sales from its Global product sales channel. Total revenue increased $264.4 million to $323.3 million driven by the successful March 2 exclusive launch of generic Flomax® ($176.2 million of revenue and $167.9 million of gross profit) and continued strong sales of generic Adderall XR® for which there were no comparable amounts in the first quarter 2009, as well as increased sales of the Company's fenofibrate products.

4 May 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical Companies, Inc. today reported results for the first quarter ended March 31, 2010.

4 May 2010

Theragenics reports highest quarterly consolidated revenue of $20.3 million

Theragenics Corporation®, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2010.

4 May 2010

CVS Caremark's net revenues increase $366M to $23.8 billion for first-quarter 2010

CVS Caremark Corporation, today announced revenues, operating profit, and net income for the three months ended March 31, 2010.

4 May 2010

Techne declares dividend of $0.26 per share for quarter ended March 31, 2010

Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.26 per share for the quarter ended March 31, 2010. The quarterly dividend will be payable May 28, 2010 to all common shareholders of record on May 14, 2010. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

From BiosPacific, Inc. 4 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

HPV test recommended for national cervical cancer screening programmes

Two studies suggest that testing for the human papillomavirus (HPV) - the major cause of cervical cancer - could be used in national cervical cancer screening programmes.

4 May 2010